- Home
- PLUR vs FINS Comparison
PLUR vs FINS Comparison
Compare PLUR & FINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLUR | FINS |
|---|---|---|
| Founded | 2001 | 2019 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9M | 429.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PLUR | FINS |
|---|---|---|
| Price | $3.04 | $13.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 47.2K | ★ 78.0K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.97% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,326,000.00 | N/A |
| Revenue This Year | $97.38 | N/A |
| Revenue Next Year | $293.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 121.74 | N/A |
| 52 Week Low | $3.02 | $11.61 |
| 52 Week High | $7.13 | $12.57 |
Technical Indicators
Market Signals| Indicator | PLUR | FINS |
|---|---|---|
| Relative Strength Index (RSI) | 38.75 | 45.02 |
| Support Level | $3.10 | $13.03 |
| Resistance Level | $3.92 | $13.27 |
| Average True Range (ATR) | 0.31 | 0.16 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 7.03 | 42.50 |
Price Performance
Historical ComparisonAbout PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
About FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.